C12N2770/32021

SENECAVIRUS A IMMUNOGENIC COMPOSITIONS AND METHODS THEREOF

The present invention relates to killed/inactivated and/or recombinant Senecavirus A immunogenic compositions and vaccines, and methods of preventing or treating animals in need of with such an immunogenic compositions and vaccines.

PROBE FOR DETECTING VIRUS
20170356912 · 2017-12-14 ·

The present invention relates to a composition comprising a probe for detecting six representative causative viruses of acute enteritis (norovirus genogroup I and genogroup II, rotavirus, hepatitis A virus, coxsackievirus, astrovirus, and adenovirus), and a DNA microarray, a kit, and a detection method comprising the composition. The present invention is effective due to high specificity and sensitivity to viruses. In addition, since the causative viruses can simply be detected at low cost compared to conventional detection methods, without expensive diagnosis devices or specialists, the present invention may be effectively used as a method for diagnosing viruses causing acute enteritis.

Recombinant Nucleic Acid of Seneca Valley Virus, Recombinant Vaccine Strain and Preparation Method and Use Thereof

The disclosure provides a recombinant nucleic acid of Seneca valley virus, a recombinant vaccine strain and preparation method and use thereof, and relates to the technical field of genetic engineering. The disclosure provides the recombinant nucleic acid of Seneca valley virus, recombinant Seneca valley virus comprising the recombinant nucleic acid, recombinant Seneca valley virus encoded by the recombinant nucleic acid, recombinant Seneca valley virus vaccine strain comprising the recombinant Seneca valley virus and preparation method and use thereof. According to the disclosure, a vaccine strain characterized by high antigen production capacity, remarkably reduced pathogenicity (even having no pathogenicity to pigs), strong antibody induction activity, high immune protection rate is prepared. The vaccine strain remarkably improves the biological safety and can be used for preventing and controlling Seneca valley virus in China and the neighboring countries.

Stable production of virulent enterovirus 71 and use thereof

Provided is a host cell for stably propagating a virulent hand, foot and mouth disease virus, the host cell expressing no heparan sulfate and overexpressing primate scavenger receptor class B member 2 (SCARB2). Also provided is a method for screening for an anti-hand, foot and mouth disease virus vaccine or an anti-hand, foot and mouth disease virus drug using a stably cultured virulent hand, foot and mouth disease virus.

ENCAPSULATED RNA POLYNUCLEOTIDES AND METHODS OF USE

The present disclosure relates to recombinant RNA molecules encoding an oncolytic virus. The present disclosure further relates to the encapsulation of the recombinant RNA molecules and the use of the recombinant RNA molecules and/or particles for the treatment and prevention of cancer.

Senecavirus a immunogenic compositions and methods thereof

The present invention relates to killed/inactivated and/or recombinant Senecavirus A immunogenic compositions and vaccines, and methods of preventing or treating animals in need of with such an immunogenic compositions and vaccines.

NUCLEIC ACID MOLECULES INSERTED EXPRESSION REGULATION SEQUENCES, EXPRESSION VECTOR COMPRISING NUCLEIC ACID MOLECLUES AND PHARMACEUTICAL USE THEREOF

A nucleic acid molecule including at least one expression control sequence having an Internal Ribosomal Entry Site (IRES) sequence, at least one coding region, and optionally multiple adenosines or thymidines upstream of the at least one expression control sequence is disclosed as an expression system. Besides, a recombinant expression vector including the nucleic acid molecule and pharmaceutical or medicinal use of the nucleic acid molecule are disclosed.

SENECAVIRUS A VIRUS STRAINS AND IMMUNOGENIC COMPOSITIONS THEREFROM

The present invention is directed to novel nucleotide sequences of Senecavirus A (“SVA”), including novel genotypes thereof, which are useful as live attenuated and other vaccine compositions for treating and preventing diseases in swine and other animals. Vaccines provided according to the practice of the invention are effective against multiple swine SVA genotypes and isolates. Diagnostic and therapeutic sequences are also a feature of the present invention, as are infectious clones useful in the propagation of the virus and in the preparation of vaccines. Particularly important aspects of the invention include polynucleotide constructs that replicate in tissue culture and in host swine. The invention also provides for novel full length SVA genomes that can replicate efficiently in host animals and tissue culture.

Attenuated porcine sapelovirus strain and immunogenic compositions therefrom

The present invention is directed to novel nucleotide and amino acid sequences of Porcine Sapelovirus (“PSV”), including novel genotypes thereof, all of which are useful in the preparation of vaccines for treating and preventing diseases in swine and other animals. Vaccines provided according to the practice of the invention are effective against multiple swine PSV genotypes and isolates. Diagnostic and therapeutic polyclonal and monoclonal antibodies are also a feature of the present invention, as are infectious clones useful in the propagation of the virus and in the preparation of vaccines. Particularly important aspects of the invention include polynucleotide constructs that replicate in tissue culture and in host swine. The invention also provides for novel full-length PSV genomes that can replicate efficiently in host animals and tissue culture.

SENECAVIRUS A IMMUNOGENIC COMPOSITIONS AND METHODS THEREOF

The present invention relates to killed/inactivated and/or recombinant Senecavirus A immunogenic compositions and vaccines, and methods of preventing or treating animals in need of with such an immunogenic compositions and vaccines.